Listed

BriaCell Therapeutics Corp.: Form 10-K for the period ended Jul 31, 2022

Filed with the SEC on Oct 28, 2022 and accepted by EDGAR at Oct 27, 2022, 18:00 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-07-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2021-08-01 to 2022-07-31$8.0mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2021-08-01 to 2022-07-31−$15.3mus-gaap:OperatingIncomeLoss
Interest expense12 months2021-08-01 to 2022-07-31$979us-gaap:InterestExpense
Net income12 months2021-08-01 to 2022-07-31−$26.8mus-gaap:NetIncomeLoss
Basic EPS12 months2021-08-01 to 2022-07-31−$1.73us-gaap:EarningsPerShareBasic
Operating cash flow12 months2021-08-01 to 2022-07-31−$12.5mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2022-07-31$41.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-07-31$42.3mus-gaap:AssetsCurrent
Total assetsAt period end2022-07-31$42.6mus-gaap:Assets
Current liabilitiesAt period end2022-07-31$941.1kus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2022-07-31$10.3mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-22-029742. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.